GlobeNewswire: Scorpius Holdings, Inc. Contains the last 10 of 161 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:09:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848546/0/en/Scorpius-Holdings-Awarded-Contract-in-Excess-of-1-Million-with-NIH-Funded-Researcher-at-a-Major-University.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University2024-03-19T12:30:00Z<![CDATA[DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university.]]>https://www.globenewswire.com/news-release/2024/03/14/2846274/0/en/Scorpius-Holdings-Accepted-as-a-Member-of-the-US-Government-s-BioMaP-Consortium.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium2024-03-14T12:30:00Z<![CDATA[Provides Access to Growth Funding and Enhanced Access to Federal Projects Provides Access to Growth Funding and Enhanced Access to Federal Projects]]>https://www.globenewswire.com/news-release/2024/03/12/2845067/0/en/Scorpius-Holdings-Inc-Announces-Closing-of-Public-Offering.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings, Inc. Announces Closing of Public Offering2024-03-12T21:00:59Z<![CDATA[DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.]]>https://www.globenewswire.com/news-release/2024/03/08/2842879/0/en/Scorpius-Holdings-Inc-Announces-Pricing-of-Public-Offering.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings, Inc. Announces Pricing of Public Offering2024-03-08T05:20:00Z<![CDATA[DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock were offered by the Company. The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/03/07/2842776/0/en/Scorpius-Holdings-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock2024-03-07T21:18:08Z<![CDATA[DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering. All of the shares of common stock are to be sold by the Company.]]>https://www.globenewswire.com/news-release/2024/03/07/2842254/0/en/Scorpius-Holdings-Estimates-Greater-than-375-Sequential-Increase-in-Revenue-for-the-Fourth-Quarter-of-2023-Compared-to-the-Third-Quarter-of-2023.html?f=22&fvtc=4&fvtv=22889Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 20232024-03-07T13:30:00Z<![CDATA[Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023]]>https://www.globenewswire.com/news-release/2024/02/06/2824233/0/en/NightHawk-Biosciences-Completes-Name-Change-to-Scorpius-Holdings-Trading-to-Commence-Under-SCPX-Effective-at-the-Market-Open-Today.html?f=22&fvtc=4&fvtv=22889NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today2024-02-06T13:00:00Z<![CDATA[DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK; SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it had completed its name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO. In connection with the name change, the Company’s ticker will change to “SCPX” effective today, February 6, 2024. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action will be required by existing shareholders.]]>https://www.globenewswire.com/news-release/2024/02/01/2821944/0/en/NightHawk-s-Scorpius-BioManufacturing-Subsidiary-Announces-the-Promotion-of-Joe-Payne-to-President-and-Chief-Operating-Officer.html?f=22&fvtc=4&fvtv=22889NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer2024-02-01T13:00:00Z<![CDATA[DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the promotion of Joe Payne to President and Chief Operating Officer (COO) of its Scorpius BioManufacturing subsidiary.]]>https://www.globenewswire.com/news-release/2024/01/30/2819927/0/en/NightHawk-Receives-Proceeds-of-3-25-Million-in-Connection-with-Sale-of-Non-Core-Intellectual-Property-and-Issuance-of-a-Low-Interest-Bearing-Note.html?f=22&fvtc=4&fvtv=22889NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note2024-01-30T13:00:00Z<![CDATA[DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced it has sold additional none-core IP. Additionally, the Company received proceeds of $2.25 million from a note issued pursuant to the terms of the previously announced divestiture of non-core assets ( the “Note”). The Note bears interest at an annual rate of 1% and, subject to stockholder approval, would be convertible into shares of NightHawk’s common stock at $0.39281 per share, an 8% premium to the closing price of the Company’s common stock on January 29, 2024.]]>https://www.globenewswire.com/news-release/2024/01/25/2816766/0/en/NightHawk-s-Scorpius-BioManufacturing-Subsidiary-Awarded-Multimillion-Dollar-Contract-with-a-Publicly-Traded-Biotech-Company-to-Support-its-Phase-2-Clinical-Program.html?f=22&fvtc=4&fvtv=22889NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program2024-01-25T13:30:00Z<![CDATA[Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturing Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturing]]>